Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  recombinant human interleukin-15
Find trials that include:  Any drugs shown
Results 1-7 of 7 for your search:
Start Over
Recombinant Interleukin-15 After Chemotherapy and Tumor Infiltrating Lymphocyte Transfer in Treating Patients With Metastatic Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0170, NCI-2013-01492, P10798, NCT01369888
Recombinant Human Interleukin-15 and Donor Natural Killer Cell Infusion in Treating Patients with Refractory or Relapsed Acute Myelogenous Leukemia
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 2014LS092, NCI-2015-00396, 9880, NCT02395822
Recombinant Interleukin-15 in Treating Patients with Metastatic Melanoma or Kidney Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 85
Trial IDs: 10-C-0021, NCI-2015-00085, 100021, 10-C-0021 G, 9850, NCT01021059
Recombinant Interleukin-15 and Donor Natural Killer Cell Therapy in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2010LS063, NCI-2011-01081, 1009M89012, MT2010-10, NCT01385423
Recombinant Interleukin-15 in Treating Patients with Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-C-0113, NCI-2013-01520, 120113, P11905, NCT01572493
Recombinant Interleukin-15 in Treating Patients with Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN11-02, NCI-2012-02205, NCT01727076
Activated Natural Killer Cells with or without Recombinant Interleukin-15 in Treating Younger Patients with Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 25
Trial IDs: 13-C-0152, NCI-2013-01215, 09-25-0099, 130152, P9493_A06PAMDREVW01, 9493, NCT01875601
Start Over